These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 12683651)

  • 1. Use of angiotensin-converting enzyme inhibitors in patients with diabetic nephropathy.
    How HY; Sibai BM
    J Matern Fetal Neonatal Med; 2002 Dec; 12(6):402-7. PubMed ID: 12683651
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diabetic nephropathy and pregnancy.
    Landon MB
    Clin Obstet Gynecol; 2007 Dec; 50(4):998-1006. PubMed ID: 17982343
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers for diabetic nephropathy: a retrospective comparison.
    Robles NR; Romero B; Fernandez-Carbonero E; Sánchez-Casado E; Cubero JJ
    J Renin Angiotensin Aldosterone Syst; 2009 Dec; 10(4):195-200. PubMed ID: 20026868
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic controversies in hypertension management: angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor blockers for diabetic nephropathy? A case for ACE inhibitors.
    Crook ED; Preddie DC
    Ethn Dis; 2002; 12(4):S3-49-52. PubMed ID: 12477155
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Risk and prevention of diabetic nephropathy].
    Ravera M; Re M; Deferrari G
    G Ital Nefrol; 2007; 24 Suppl 38():13-9. PubMed ID: 17922442
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [ACE inhibitors and early diabetic nephropathy].
    Bangstad HJ; Hartmann A; Berg TJ; Hanssen KF
    Tidsskr Nor Laegeforen; 1995 Oct; 115(24):3039-41. PubMed ID: 7570536
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bradykinin B2 receptors as a target in diabetic nephropathy.
    Doggrell SA
    Curr Opin Investig Drugs; 2006 Mar; 7(3):251-5. PubMed ID: 16555685
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An evidence-based review of ACE inhibitors in incipient diabetic nephropathy.
    Haider A; Oh P; Peloso PM
    Can J Clin Pharmacol; 2000; 7(2):115-9. PubMed ID: 10958708
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus. A 7-year follow-up study.
    Ravid M; Lang R; Rachmani R; Lishner M
    Arch Intern Med; 1996 Feb; 156(3):286-9. PubMed ID: 8572838
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Progression of chronic renal insufficiency and its prevention using angiotensin converting enzyme inhibitors and angiotensin antagonists].
    Tesar V
    Vnitr Lek; 2003 May; 49(5):365-9. PubMed ID: 12908169
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic effects of angiotensin II inhibition or blockade on the progression of chronic renal disease.
    Cantarovich F; Rangoonwala B
    Int J Clin Pract; 2003 Nov; 57(9):801-22. PubMed ID: 14686572
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Renal protection and angiotensin converting enzyme inhibition in microalbuminuric type I and type II diabetic patients.
    Cooper ME
    J Hypertens Suppl; 1996 Dec; 14(6):S11-4. PubMed ID: 9023709
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers for prevention and treatment of nephropathy associated with type 2 diabetes mellitus.
    Hughes DB; Britton ML
    Pharmacotherapy; 2005 Nov; 25(11):1602-20. PubMed ID: 16232022
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Losartan in diabetic nephropathy.
    Perico N; Ruggenenti P; Remuzzi G
    Expert Rev Cardiovasc Ther; 2004 Jul; 2(4):473-83. PubMed ID: 15225108
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Prevention and remission of diabetic nephropathy].
    Sugimoto T; Nakamura Y; Makino H
    Nihon Rinsho; 2003 Jul; 61(7):1167-71. PubMed ID: 12877079
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Type 2 diabetes and nephropathy--new studies, new treatment strategies?].
    Os I; Stenehjem A; Høieggen A; Draganov B; Jenssen T; Holdaas H
    Tidsskr Nor Laegeforen; 2002 Apr; 122(9):918-20. PubMed ID: 12082835
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of genetic variation on therapy with angiotensin converting enzyme inhibitors or angiotensin receptor blockers in dialysis patients.
    Böger CA; Götz AK; Krüger B; Hösl M; Schmitz G; Riegger GA; Krämer BK
    Eur J Med Res; 2005 Apr; 10(4):161-8. PubMed ID: 15946912
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Role of the renin-angiotensin system in the pathogenesis, clinical picture and treatment of diabetic nephropathy].
    Wittmann I; Degrell P; Komáromy A; Molnár GA; Wagner Z; Wagner L; Mazák I; Nagy J
    Orv Hetil; 2003 Mar; 144(13):613-9. PubMed ID: 12728786
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical use of angiotensin-converting enzyme inhibitors in patients with renal impairment.
    Elliott HL
    Blood Press Suppl; 1994; 2():31-4. PubMed ID: 8061843
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Resolution of early stage diabetic nephropathy in an obese diabetic patient after gastric bypass.
    Pérez G; Devaud N; Escalona A; Downey P
    Obes Surg; 2006 Oct; 16(10):1388-91. PubMed ID: 17059753
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.